Press Releases

Date Title  
Toggle Summary Natera Launches Quantification Technique to Enhance Prospera™ Test Precision; Initiates PEDAL Study for New Insights
Quantifying background cfDNA increases accuracy of dd-cfDNA testing SAN CARLOS, Calif. , June 1, 2020 /PRNewswire/ --   Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, is pleased to announce the launch of a novel technique to enhance results from the Prospera
Toggle Summary Natera Announces New Prospera™ Data at ATC Showcasing Innovation in Cell-Free DNA
New research on background cell-free DNA to refine transplant rejection risk SAN CARLOS, Calif. , May 26, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its Prospera donor-derived cell-free DNA
Toggle Summary Natera Announces New Data at ASCO Highlighting Utility of Personalized MRD Monitoring
Results from the first large, real-world study in 535 gastrointestinal (GI) cancer patients using Signatera™ MRD testing New data using Signatera to monitor treatment response with an immunotherapy-based regimen in hepatocellular carcinoma SAN CARLOS, Calif.
Toggle Summary Natera and Illumina Settle Patent Dispute
SAN CARLOS, Calif. and SAN DIEGO , May 18, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, and Illumina Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing platforms, today announced that they have settled their patent
Toggle Summary Natera to Present at the UBS Virtual Global Healthcare Conference
SAN CARLOS, Calif. , May 13, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the UBS Virtual Global Healthcare Conference on Monday, May 18, 2020 at 12:50 p.m. PT ( 3:50 p.m. ET ).
Toggle Summary Prospera™ Receives Positive Medicare Coverage
SAN CARLOS, Calif. , May 11, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Noridian, a Medicare Administrative Contractor (MAC), has issued positive coverage for the Prospera donor-derived cell-free DNA (dd-cfDNA) test.
Toggle Summary Natera Reports First Quarter 2020 Financial Results
SAN CARLOS, Calif. , May 6, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the first quarter ended March 31, 2020 and provided an update on recent business progress.
Toggle Summary Natera Announces Achievement of Key Recruitment Milestones in ProActive Study and Success in Prospera™ Early Access Program
SAN CARLOS, Calif. , May 4, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced the achievement of key recruitment milestones in the ProActive registry study and success in the Prospera early access program.  The ProActive study
Toggle Summary Natera Announces First Quarter 2020 Earnings Conference Call
SAN CARLOS, Calif. , April 29, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its first quarter ended March 31, 2020 , after the market close on May 6, 2020 .
Toggle Summary Natera Asserts Three New Oncology Patents Against ArcherDX
Extends leadership position in personalized, tumor-informed MRD testing SAN CARLOS, Calif. , April 15, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today asserted three recently issued oncology patents against ArcherDX in its ongoing

Footer disclaimer

Footer disclaimer

© Natera 2020. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.